𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Concurrent Chemoradiation with Carboplatin and Paclitaxel with or without Concomitant Boost in Advanced Inoperable Head and Neck Cancers - Efficacy and Toxicity

✍ Scribed by S.I. Temming; M. Kocher; J. Klussmann; S. Preuss; O. Guntinas-Lichius; R. Semrau; R.P. Müller

Book ID
108150322
Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
40 KB
Volume
75
Category
Article
ISSN
0360-3016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized phase 2 study of concomitant
Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer
✍ Robert Haddad; Stephen Sonis; Marshall Posner; Lori Wirth; Rosemary Costello; Pa 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 272 KB 👁 1 views

## Abstract ## BACKGROUND: A randomized phase 2 study was performed to investigate the efficacy/toxicity of combining concomitant boost radiation and weekly carboplatin/paclitaxel with or without amifostine in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). ##

Concomitant radiochemotherapy in primary
Concomitant radiochemotherapy in primary inoperable advanced head and neck cancer with 5-fluorouracil and mitomycin-C
✍ Hans Christiansen; Robert M. Hermann; Andrea Hille; Elisabeth Weiss; Mirko Nitsc 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 534 KB

## Abstract ## Background. The purpose of this study was to evaluate the efficacy and toxicity of radiotherapy and concomitant 5‐fluorouracil (5‐FU) and mitomycin‐C infusion in inoperable head and neck cancer. ## Methods. Seventy‐six patients (86% men, 14% women), mean age 57 years, with primary

IMRT using simultaneous integrated boost
IMRT using simultaneous integrated boost (66 Gy in 6 weeks) with and without concurrent chemotherapy in head and neck cancer – toxicity evaluation
✍ Milan VOŠMIK; Petr KORDAČ; Petr PALUSKA; Milan ZOUHAR; Jiří PETERA; Karel ODRÁŽK 📂 Article 📅 2008 🏛 Wielkopolskie Centrum Onkologii 🌐 Polish ⚖ 308 KB

To evaluate the toxicity of intensity-modulated radiotherapy with simultaneous integrated boost (SIB-IMRT) in head and neck cancer patients treated using a protocol comprising 66 Gy to the PTV1 (planning target volume; region of macroscopic tumour) and 60 Gy and 54 Gy to the regions with high risk (

Phase I trial and pharmacokinetics of es
Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma
✍ Philip C. Amrein; John R. Clark; Jeffrey G. Supko; Richard L. Fabian; Chiu C. Wa 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB 👁 1 views

## Abstract ## BACKGROUND Amifostine was developed to protect normal tissues from radiation exposure. The current study was undertaken to determine whether amifostine would allow the delivery of greater numbers of weekly paclitaxel treatments with concomitant, hyperfractionated radiotherapy in pat

Concurrent chemoradiotherapy with weekly
Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a Brown University Oncology Group Phase II Study (HN-53)
✍ Prakash B. Chougule; Muhammad S. Akhtar; Ritesh Rathore; James Koness; Robert Mc 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 1 views

## Abstract ## Background. A phase II study was conducted using concurrent paclitaxel, carboplatin, and external beam radiotherapy (RT) in patients with advanced head and neck cancer. ## Methods. Forty‐three patients (stage III, __n__ = 12; stage IV, __n__ = 31) were treated with 8 cycles of wee